The Impact Of Antiphospholipid Syndrome On Pregnancy Complications At Different Gestational Stages And The Influence Of Combined Therapeutic Approaches

Authors

  • Humbatova Leyla Ilgarovna
  • Shulcheva Anastasia Sergeevna
  • Anufrieva Alina Aleksandrovna
  • Yudichev Nikita Andreevich
  • Korshunova Arina Ivanovna
  • Bryksina Elena Sergeevna
  • Khuzhakulov Dzhonibek Khoshimzhonovich
  • Pavlov Bogdan Vladimirovich

Keywords:

pregnancy, antiphospholipid syndrome, preeclampsia, placental insufficiency, heparin therapy, aspirin

Abstract

The prevalence of antiphospholipid syndrome (APS) varies across different regions of the world, ranging from 1 to 50 cases per 100,000 individuals, with a higher incidence among women compared to men. Pregnancy in women with APS is associated with an increased risk of adverse outcomes, including a higher likelihood of placental insufficiency, preeclampsia, intrauterine growth restriction, miscarriage, stillbirth, and low birth weight relative to gestational age. Antiphospholipid antibodies (aPL) exert their pathogenic effects through multiple mechanisms, including an increase in circulating placental extracellular vesicles that induce endothelial dysfunction; disruption of trophoblast proliferation, differentiation, and apoptosis; mitochondrial DNA release into the cytoplasm, triggering Toll-like receptor activation and sterile inflammation in the placenta; among other pathways. These mechanisms contribute to the detrimental effects of aPL throughout pregnancy.

The aim of this review is to examine the impact of APS on all stages of pregnancy and to analyze recent trends in APS management during pregnancy. A review of the literature indicates that lupus anticoagulant (particularly in women with systemic lupus erythematosus) significantly increases the risk of adverse pregnancy outcomes. In other cases, unrelated to systemic lupus erythematosus, pathological effects have been demonstrated for antibodies targeting cardiolipin, β2-glycoprotein I, and phosphatidylserine/prothrombin, which elevate the likelihood of pregnancy complications. The cornerstone of APS treatment during pregnancy is the administration of low-dose aspirin and low-molecular-weight heparin, achieving favorable pregnancy outcomes in 70–80% of cases. The addition of pravastatin or hydroxychloroquine enhances the efficacy of this standard therapy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Genovese H.G., McQueen D.B. The prevalence of sporadic and recurrent pregnancy loss. Fertil Steril. 2023 Nov;120(5):934-936. doi: 10.1016/j.fertnstert.2023.08.954.

Amrieva D.X., Ol`mesova A.R., Sklyarova S.A., Petrov Yu.A. Antiphospholipid syndrome as a cause of miscarriage. International journal of applied and fundamental research. 2019;9:100-103. (In Russian).

Dabit J.Y., Valenzuela-Almada M.O., Vallejo-Ramos S., Duarte-García A. Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep. 2022;23(12):85. doi: 10.1007/s11926-021-01038-2.

Foddai S.G., Radin M., Cecchi I., et al. The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities. J Thromb Haemost. 2020 Nov;18(11):2921-2928. doi: 10.1111/jth.15053.

Schreiber K., Hunt B.J. Managing antiphospholipid syndrome in pregnancy. Thromb Res. 2019;181 Suppl 1:S41-S46. doi: 10.1016/S0049-3848(19)30366-4.

Petri M. Antiphospholipid syndrome. Transl Res. 2020;225:70-81. doi: 10.1016/j.trsl.2020.04.006.

Yelnik C.M., Laskin C.A., Porter T.F., et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016;3(1):e000131. doi: 10.1136/lupus-2015-000131.

Manning J.E., Arachchillage D.J. Dilemmas in the diagnosis and management of antiphospholipid syndrome. J Thromb Haemost. 2024;22(8):2156-2170. doi: 10.1016/j.jtha.2024.03.027.

Ripoll V.M., Pregnolato F., Mazza S., et al. Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. J Autoimmun. 2018;93:114–123. doi: 10.1016/j.jaut.2018.07.002.

Kim M.Y., Guerra M.M., Kaplowitz E., et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018;77(4):549–555. doi: 10.1136/annrheumdis-2017-212224.

De Groot P.G., Derksen R.H. Pathophysiology of antiphospholipid antibodies, Neth. J. Med. 2004;62:267–272.

Petronijević S.V., Vilotić A., Bojić-Trbojević Ž., et al. Trophoblast Cell Function in the Antiphospholipid Syndrome. Biomedicines. 2023;11(10):2681. https://doi.org/10.3390/biomedicines11192681.

Shamonki J.M., Salmon J.E., Hyjed E., et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. American Journal of Obstetrics and Gynecology. 2007;196(2):167.e1-167.e5. https://doi.org/10.1016/j.ajog.2006.10.879.

Tong M., Johansson C., Xiao F., et al. Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia. Sci Rep. 2017;7(1):16556. doi: 10.1038/s41598-017-16448-5.

Possomato-Vieira J.S., Khalil R.A. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol. 2016;77:361-431. doi: 10.1016/bs.apha.2016.04.008.

Shehata H., Ali A., Silva-Edge M., et al. Thrombophilia screening in women with recurrent first trimester miscarriage: is it time to stop testing? - a cohort study and systematic review of the literature. BMJ Open. 2022;12(7):e059519. doi: 10.1136/bmjopen-2021-059519.

Gibbins K.J., Mumford S.L., Sjaarda L.A., et al. Preconception antiphospholipid antibodies and risk of subsequent early pregnancy loss. Lupus. 2018;27(9):1437-1445. doi: 10.1177/0961203318776089.

Larosa M., Le Guern V., Guettrot-Imbert G., et al. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study. Rheumatology (Oxford). 2022;61(9):3657-3666. doi: 10.1093/rheumatology/keab943.

Silver R.M., Parker C.B., Reddy U.M., et al., Antiphospholipid antibodies in stillbirth, Obstet. Gynecol. 2013;122:641–657. doi: 10.1097/AOG.0b013e3182a1060e.

Peaceman A.M. Antiphospholipid Antibodies in Stillbirth. Obstetrics & Gynecology. 2014;123(1):184. doi:10.1097/aog.0000000000000071.

Belhocine M., Coutte L., Martin Silva N., et al. Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women. Arthritis Res Ther. 2018;20(1):249. doi: 10.1186/s13075-018-1745-2.

Amikam U., Hochberg A., Shenhav M., et al. Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at >34 Weeks of Gestation. J Clin Med. 2023;12(13):4516. doi: 10.3390/jcm12134516.

Do Prado A.D., Piovesan D.M., Staub H.L., Horta B.L. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta- analysis, Obstet. Gynecol. 2010;116:1433-1443. doi: 10.1097/AOG.0b013e3181fe02ec.

Zemet R., Dulitzki M., Baum M., et al. Early-onset preeclampsia - The impact of antiphospholipid antibodies on disease severity. Eur J Obstet Gynecol Reprod Biol. 2021;263:79-84. doi: 10.1016/j.ejogrb.2021.06.006.

Gibbins K.J., Tebo A.E., Nielsen S.K., Branch D.W. Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study. Lupus. 2018;27(12):1903-1910. doi: 10.1177/0961203318787035.

Ferrer-Oliveras R., Llurba E., Cabero-Roura L., Alijotas-Reig J. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. Lupus. 2012;21(3):257-63. doi: 10.1177/0961203311425520.

Page J.M., Blue N.R., Silver R.M. Fetal Growth and Stillbirth. Obstet Gynecol Clin North Am. 2021;48(2):297-310. doi: 10.1016/j.ogc.2021.03.001.

Canti V., Del Rosso S., Tonello M., et al. Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia. J Rheumatol. 2018;45(9):1263-1272. doi: 10.3899/jrheum.170751.

Xi F., Cai Y., Lv M., et al. Anticardiolipin Positivity Is Highly Associated With Intrauterine Growth Restriction in Women With Antiphospholipid Syndrome. Clin Appl Thromb Hemost. 2020;26:1076029620974455. doi: 10.1177/1076029620974455.

Xu J., Chen D., Tian Y., et al. Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis. Int J Clin Pract. 2022;2022:4308470. doi: 10.1155/2022/4308470.

Saccone G., Berghella V., Maruotti G.M., et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525.e1-525.e12. doi: 10.1016/j.ajog.2017.01.026.

Bramham K., Hunt B.J., Germain S., et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19(1):58-64. doi: 10.1177/0961203309347794.

Liu X., Qiu Y., Yu E.D., et al. Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis. Am J Reprod Immunol. January 2020:e13219. doi: 10.1111/aji.13219.

Duley L., Meher S., Hunter K.E., et al. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10). doi: 10.1002/14651858.CD004659.pub3.

Ziakas P.D., Pavlou M., Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010 Jun;115(6):1256-1262. doi: 10.1097/AOG.0b013e3181deba40.

Hamulyák E.N., Scheres L.J.J., Goddijn M., Middeldorp S. Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome – What is the evidence? J Thromb Haemost. 2021 May;19(5):1174-1185. doi: 10.1111/jth.15290.

Stephenson M.D., Ballem P.J., Tsang P., et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004 Aug;26(8):729-34. doi: 10.1016/s1701-2163(16)30644-2.

Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice bulletin No. 132: antiphospholipid syndrome. Obstet Gynecol. 2012;120(6):1514–1521. doi: 10.1097/01.AOG.0000423816.39542.0f.

Ruffatti A., Favaro M., Calligaro A., et al. Management of pregnant women with antiphospholipid antibodies. Expert Rev Clin Immunol. 2019;15(4):347-358. doi: 10.1080/1744666X.2019.1565995.

Kupferminc M.J., Kliger C., Rimon E., et al. Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study. J Matern Fetal Neonatal Med. 2022;35(25):8055-8061. doi: 10.1080/14767058.2021.1940940.

Lefkou E., Mamopoulos A., Dagklis T., et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933-40. doi: 10.1172/JCI86957.

Sciascia S., Hunt B.J., Talavera-Garcia E., et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214(2):273.e1-273.e8. doi: 10.1016/j.ajog.2015.09.078.

Latino J.O., Udry S., Aranda F., et al. Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine. Lupus. 2020;29(13):1736-1742. doi: 10.1177/0961203320952850.

Downloads

Published

2025-05-30

How to Cite

1.
Ilgarovna HL, Sergeevna SA, Aleksandrovna AA, Andreevich YN, Ivanovna KA, Sergeevna BE, Khoshimzhonovich KD, Vladimirovich PB. The Impact Of Antiphospholipid Syndrome On Pregnancy Complications At Different Gestational Stages And The Influence Of Combined Therapeutic Approaches. J Neonatal Surg [Internet]. 2025May30 [cited 2025Oct.23];14(8):154-63. Available from: https://www.jneonatalsurg.com/index.php/jns/article/view/6813